What to watch for as J&J gets ready to split into two separate companies next year

Johnson & Johnson is preparing next year to spin off its consumer health unit into a publicly traded company separate from its pharmaceutical and medical technology operations. Ahead of the split, Morgan Stanley put out a research note, highlighting some of the debates in the market over the move, which would result in a consumer brands company called Kenvue and a pharma company with the J & J moniker.

The company's approved and pending treatments for blood cancer and multiple myeloma are "underappreciated," Morgan Stanley said. The analysts added that the multiple myeloma market will grow to about $33 billion in 2030 — and by that time, J & J's therapies could take more than 80% of that market share.

Interesting...

will they both be called Johnson?

Is this to dodge the up and coming lawsuits?

대한민국 최근 뉴스, 대한민국 헤드 라인

Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.

The Stock Market Has Been Full of Drama in 2022, and It’s Masking Investing OpportunitiesThere was a lot of drama in the stock market this year. But for patient investors, that means opportunity.
출처: WSJ - 🏆 98. / 63 더 많은 것을 읽으십시오 »

Finding the market tough right now? Here's how young investors can be smart with their moneyInvesting was hot earlier in the pandemic, but not anymore. Analysts share with CNBC Make It their top investing tips for a volatile market. MakeIt You CNBC hacks make me laugh MakeIt Gold is at an all time high. Now is the time to sell gold and not buy it. Owners of gold are pushing the sales so that the value will continue to increase.
출처: CNBC - 🏆 12. / 72 더 많은 것을 읽으십시오 »